Bristol-Myers Squibb Co  

(Public, NYSE:BMY)   Watch this stock  
Find more results for BMY
74.81
-1.66 (-2.17%)
Real-time:   2:27PM EDT
NYSE real-time data - Disclaimer
Currency in USD
Range 74.50 - 76.48
52 week 51.82 - 77.12
Open 75.41
Vol / Avg. 5.03M/5.85M
Mkt cap 127.23B
P/E 79.92
Div/yield 0.38/2.03
EPS 0.94
Shares 1.66B
Beta 0.53
Inst. own 75%
Jul 28, 2016
Q2 2016 Bristol-Myers Squibb Co Earnings Call
Jul 28, 2016
Q2 2016 Bristol-Myers Squibb Co Earnings Release
Jun 7, 2016
Bristol-Myers Squibb Co at Goldman Sachs Global Healthcare Conference
Jun 4, 2016
Bristol-Myers Squibb Co to Discuss ASCO Highlights
May 4, 2016
Bristol-Myers Squibb Co at Deutsche Bank Health Care Conference
May 4, 2016
Bristol-Myers Squibb Co Annual Shareholders Meeting (Estimated)
May 3, 2016
Bristol-Myers Squibb Co Annual Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin 27.47% 9.85%
Operating margin 37.58% 8.57%
EBITD margin - 16.27%
Return on average assets 15.20% 4.98%
Return on average equity 33.46% 10.75%
Employees 25,000 -
CDP Score - 100 C

Address

345 PARK AVE
NEW YORK, NY 10154
United States - Map
+1-212-5464000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia

Description

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience; cardiovascular, and neuroscience. Its late-stage investigational compounds that are in Phase III clinical trials include Beclabuvir, BMS-663068 and Prostvac.

Officers and directors

Giovanni Caforio M.D. Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Charles A. Bancroft Chief Financial Officer, Executive Vice President
Age: 56
Bio & Compensation  - Reuters
Louis S. Schmukler President - Global Manufacturing and Supply
Age: 60
Bio & Compensation  - Reuters
Francis M. Cuss Executive Vice President, Chief Scientific Officer
Age: 61
Bio & Compensation  - Reuters
Sandra Leung Executive Vice President, General Counsel and Corporate Secretary
Age: 55
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Murdo Gordon Executive Vice President, Chief Commercial Officer
Age: 50
Bio & Compensation  - Reuters
Paul von Autenried Senior Vice President - Enterprise Services, Chief Information Officer
Age: 54
Bio & Compensation  - Reuters
Anne Nielsen Senior Vice President, Chief Compliance and Ethics Officer
Age: 55
Bio & Compensation  - Reuters
Joseph C. Caldarella Senior Vice President, Corporate Controller
Age: 60
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Ann Powell Judge Senior Vice President - Global Human Resources
Age: 50
Bio & Compensation  - Reuters